参考文献/References:
[1] Kargiotis O, Tsivgoulis G. The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy[J]. Curr Opin Neurol, 2021, 34(1): 45-54.
[2] 刘新峰,孙文,朱武生,等.中国急性缺血性脑卒中早期血管内介入诊疗指南2018[J].中华神经科杂志,2018,51(9):683-691.
[3] Naylor AR, Rantner B, Ancetti S, et al. European society for vascular surgery(ESVS)2023 Clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease[J]. Eur J Vasc Endovasc Surg, 2022(22): S1078-5884(22)00237.
[4] 刘新峰,朱武生,孙文,等.中国缺血性脑血管病血管内介入诊疗指南2015[J].中华神经科杂志,2015,48(10):830-837.
[5] 中国缺血性脑血管病非急诊介入治疗术前评估专家共识[J].中华内科杂志,2020,59(4):277-285.
[6] Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/ SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease:executive summary:a report of the american college of cardiology foundation/american heart association task force on practice guidelines, and the american stroke association,american association of neuroscience nurses, american association of neurological surgeons, american college of radiology, american society of neuroradiology, congress of neurological surgeons, society of atherosclerosis imaging and prevention, society for cardiovascular angiography and interventions, society of interventional radiology, society of neurointerventional surgery, society for vascular medicine, and society for vascular surgery. developed in collaboration with the american academy of neurology and society of cardiovascular computed tomography[J]. Catheter Cardiovasc Interv, 2013, 81(1): E76-123.
[7] Sussman ES, Jin M, Pendharkar AV, et al. Dual antiplatelet therapy after carotid artery stenting:trends and outcomes in a large National database[J]. J Neurointerv Surg, 2021, 13(1): 8-13.
[8] Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity[J]. Circulation, 2003, 107(23): 2908-2913.
[9] Jeong YH, Hwang JY, Kim IS, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction:results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI(ACCEL-AMI)study[J]. Circ Cardiovasc Interv, 2010, 3(1): 17-26.
[10] Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the Plato trial[J]. Lancet(London, England), 2010, 376(9749): 1320-1328.
[11] Pereira NL, Farkouh ME, So D, et al. Effect of genotype-Guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention:the TAILOR-PCI randomized clinical trial[J]. JAMA, 2020, 324(8): 761-771.
[12] Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes[J]. N Engl J Med, 2019, 381(16): 1524-1534.
[13] Wang Y, Meng X, Wang A, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med, 2021, 385(27): 2520-2530.
[14] Honig A, Sacagiu T, Filioglo A, et al. Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis[J]. J Neurol Sci, 2021, 425: 117450.
[15] Kim BJ, Kwon S, Park JH, et al. Cilostazol versus aspirin in ischemic stroke patients with High-Risk cerebral hemorrhage: subgroup analysis of the PICASSO trial[J]. Stroke, 2020, 51(3): 931-937.
[16] Kim SM, Jung JM, Kim BJ, et al. Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and Meta-Analysis[J]. Stroke, 2019, 50(12): 3503-3511.
[17] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11): 1045-1057.
[18] Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med, 2020, 383(3): 207-217.
[19] Wang Y, Chen W, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial[J]. BMJ, 2019, 365(8202): l2211.
[20] Ghamraoui AK, Ricotta J2. Outcomes and strategy of tailored antiplatelet therapy with ticagrelor in patients undergoing transcarotid artery revascularization[J]. J Vasc Surg, 2021, 73(1): 132-141.
[21] Marcaccio CL, Patel PB, Liang P, et al. Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting[J]. J Vasc Surg, 2022, 75(4): 1293-1303.e8.
[22] Delvoye F, Maier B, Escalard S, et al. Antiplatelet therapy during emergent extracranial internal carotid artery stenting: comparison of three intravenous antiplatelet perioperative strategies[J]. J Stroke Cerebrovasc Dis, 2021, 30(2): 105521.
[23] Cervo A, Ferrari F, Barchetti G, et al. Use of cangrelor in cervical and intracranial stenting for the treatment of acute ischemic stroke:a 《real Life》 single-center experience[J]. AJNR Am J Neuroradiol, 2020, 41(11): 2094-2099.
[24] Aguilar-Salinas P, Agnoletto GJ, Brasiliense LC, et al. Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology:preliminary experience in a single-center pilot study[J]. J Neurointerv Surg, 2019, 11(4): 347-351.
[25] 霍晓川,高峰.急性缺血性卒中血管内治疗中国指南2018[J].中国卒中杂志,2018,13(7):706-729.
[26] 替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J].中国卒中杂志, 2019, 14(10): 1034-1044.
[27] Sun L, Zhang J, Song Y, et al. Safety and efficacy of tirofiban in rescue treatment for acute intracranial intraprocedural stent thrombosis[J]. Front Neurol, 2020, 11: 492.
[28] Sun L, Zhang J, Song Y, et al. Safety and efficacy of prophylactic tirofiban infusion for acute intracranial intraprocedural stent thrombosis[J]. Sci Rep, 2021, 11(1): 21326.
[29] Gruber P, Hlavica M, Berberat J, et al. Acute administration of tirofiban versus aspirin in emergent carotid artery stenting[J]. Interventional Neuroradiology, 2019, 25(2): 219-224.
[30] Thiele H, Wöhrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial[J]. Lancet(London, England), 2012, 379(9819): 923-931.
[31] Kansagra AP, Mceachern JD, Madaelil TP, et al. Intra-arterial versus intravenous abciximab therapy for thromboembolic complications of neuroendovascular procedures: case review and meta-analysis[J]. J Neurointerv Surg, 2017, 9(2): 131-136.
[32] Walsh RD, Barrett KM, Aguilar MI, et al. Intracranial hemorrhage following neuroendovascular procedures with abciximab is associated with high mortality: a multicenter series[J]. Neurocrit Care, 2011, 15(1): 85-95.
[33] Delgado F, Oteros R, Jimenez-Gomez E, et al. Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment[J]. J Neurointerv Surg, 2019, 11(2): 147-152.
[34] Bath PM, Woodhouse LJ, Appleton JP, et al. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT[J]. Health Technol Assess, 2018, 22(48): 1-76.
[35] Bath PM, Woodhouse LJ, Appleton JP, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia(TARDIS): a randomised, open-label, phase 3 superiority trial[J]. Lancet(London, England), 2018, 391(1123): 850-859.
[36] Amarenco P. Learning from TARDIS: time for more focused trials in stroke prevention[J]. Lancet(London, England), 2018, 391(1123): 819-821.
[37] Nakagawa I, Wada T, Park HS, et al. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis[J]. J Vasc Surg, 2014, 59(3): 761-767.
[38] Toyoda K, Omae K, Hoshino H, et al. Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: a CSPS.com trial post Hoc analysis[J]. Neurology, 2022, 98(10): e983-e992.
[39] Wu Z, Liu AF, Zhou J, et al. The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease[J]. J Neurointerv Surg, 2019, 11(4): 352-356.
[40] Nakagawa I, Park HS, Wada T, et al. Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting[J]. Neurol Res, 2017, 39(8): 695-701.
[41] Jia B, Zhang X, Ma N, et al. Comparison of Drug-Eluting stent with Bare-Metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis: a randomized clinical trial[J]. JAMA Neurol, 2022, 79(2): 176-184.
[42] O'gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the american college of cardiology foundation/american heart association task force on practice guidelines[J]. Circulation, 2013, 127(4): e362-e425.
[43] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention:a report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions[J]. Circulation, 2011, 124(23): e574-e651.
[44] Chen XP, Huang QH, Hong B, et al. Drug-eluting stent for the treatment of symptomatic vertebral origin stenosis: long-term results[J]. J Clin Neurosci, 2011, 18(1): 47-51.
[45] Vajda Z, Aguilar M, Göhringer T, et al. Treatment of intracranial atherosclerotic disease with a balloon-expandable paclitaxel eluting stent: procedural safety, efficacy and mid-term patency[J]. Clin Neuroradiol, 2012, 22(3): 227-233.